Form 8-K - Current report:
SEC Accession No. 0001601485-25-000072
Filing Date
2025-05-13
Accepted
2025-05-13 16:27:01
Documents
22
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K angn-20250513.htm   iXBRL 8-K 24587
2 EX-99.1 a2025-05x13xxeltxxx1q25f.htm EX-99.1 18466
6 a2025-05x13xxeltxxx1q25f001.jpg GRAPHIC 206709
7 a2025-05x13xxeltxxx1q25f002.jpg GRAPHIC 125326
8 a2025-05x13xxeltxxx1q25f003.jpg GRAPHIC 88913
9 a2025-05x13xxeltxxx1q25f004.jpg GRAPHIC 77691
10 a2025-05x13xxeltxxx1q25f005.jpg GRAPHIC 263632
11 a2025-05x13xxeltxxx1q25f006.jpg GRAPHIC 245021
12 a2025-05x13xxeltxxx1q25f007.jpg GRAPHIC 256866
13 a2025-05x13xxeltxxx1q25f008.jpg GRAPHIC 31357
  Complete submission text file 0001601485-25-000072.txt   1964722

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT angn-20250513.xsd EX-101.SCH 1870
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT angn-20250513_lab.xml EX-101.LAB 22786
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT angn-20250513_pre.xml EX-101.PRE 13130
25 EXTRACTED XBRL INSTANCE DOCUMENT angn-20250513_htm.xml XML 2907
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39990 | Film No.: 25940581
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)